Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Change in Cash (2016 - 2025)

Historic Change in Cash for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q3 2025 value amounting to -$11.0 million.

  • Vanda Pharmaceuticals' Change in Cash fell 34629.48% to -$11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$30.5 million, marking a year-over-year increase of 6314.5%. This contributed to the annual value of -$33.5 million for FY2024, which is 433042.93% down from last year.
  • Latest data reveals that Vanda Pharmaceuticals reported Change in Cash of -$11.0 million as of Q3 2025, which was down 34629.48% from -$30.8 million recorded in Q2 2025.
  • Vanda Pharmaceuticals' 5-year Change in Cash high stood at $219.1 million for Q1 2023, and its period low was -$204.1 million during Q2 2023.
  • Over the past 5 years, Vanda Pharmaceuticals' median Change in Cash value was -$6.8 million (recorded in 2021), while the average stood at $467263.2.
  • As far as peak fluctuations go, Vanda Pharmaceuticals' Change in Cash skyrocketed by 542821.17% in 2022, and later crashed by 224562.79% in 2023.
  • Vanda Pharmaceuticals' Change in Cash (Quarter) stood at $1.5 million in 2021, then soared by 5428.21% to $85.6 million in 2022, then plummeted by 155.31% to -$47.4 million in 2023, then surged by 103.84% to $1.8 million in 2024, then plummeted by 702.58% to -$11.0 million in 2025.
  • Its Change in Cash was -$11.0 million in Q3 2025, compared to -$30.8 million in Q2 2025 and $9.5 million in Q1 2025.